NCT03654131Active, not recruitingPhase 2
Microwave Ablation Versus Stereotactic Body Radiotherapy for Colorectal Liver Metastases in Oligometastatic Disease: a Prospective, Randomised, Phase 2 Trial
Stereotactic Body Radiation Therapy vs. Microwave Ablation for Colorectal Cancer Patients With Metastatic Disease in the Liver - a Randomized Phase II Trail
Source: ClinicalTrials.gov · Last updated 19 Mar 2026
Brief summary (registry, in English)
The LAVA-CRLM trial (Local Ablation Versus Ablative radiotherapy in ColoRectal Liver Metastases) is a prospective, randomised, phase 2 study designed to compare local control and safety of microwave ablation (MWA) versus stereotactic body radiotherapy (SBRT)in patients with colorectal liver metastases and oligometastatic disease. Primary endpoint is freedom form local lesion progression.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (actual)
- First submitted
- 27 Aug 2018
- Start date
- 25 Jul 2018
- Primary completion date
- 1 Jan 2026
- Lead sponsor
- Copenhagen University Hospital, Rigshospitalet
- Diseases
- Colorectal cancer
- NCT number
- NCT03654131
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 100
- From 25 Jul 2018 to the primary completion date, 1 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous radiotherapy to the liver
Other illness
- Another active cancer disease within the past 36 months
Other
- Liver volume \< 700 ml
- Not able to understand written or oral protocol information
Who the study is looking for
- Colorectal cancer patients with oligo metastatic disease in the liver (1 to 3 tumors), and where metastases are found unsuitable for resection because of
- non-resectability
- small metastasis localized deep in the liver, where a parenchyma sparing intervention is preferred over an extensive resection
- previous extensive liver surgery
- comorbidity
- The multidisciplinary team should all agree that both percutaneous or open surgical MW-ablation and SBRT are safe as first treatment choice for the individual patient.
- Tumor sizes ≤4.0 cm
- Age \> 18 years
- Signed informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Righospitalet Coordinator of this site? Confirm its status | Copenhagen | Denmark | Unknown status |
Related publications
- Microwave ablation versus stereotactic body radiotherapy for oligometastatic colorectal liver metastases (LAVA-CRLM): a prospective, randomised, phase II trial.Lancet Reg Health Eur · 2026 · PMID 42829779
This page is information, not medical advice. Discuss any trial with your doctor.